JP2023554198A5 - - Google Patents

Info

Publication number
JP2023554198A5
JP2023554198A5 JP2023559173A JP2023559173A JP2023554198A5 JP 2023554198 A5 JP2023554198 A5 JP 2023554198A5 JP 2023559173 A JP2023559173 A JP 2023559173A JP 2023559173 A JP2023559173 A JP 2023559173A JP 2023554198 A5 JP2023554198 A5 JP 2023554198A5
Authority
JP
Japan
Prior art keywords
expression vector
intron
fragment
variant
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023559173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554198A (ja
JP7889870B2 (ja
Filing date
Publication date
Priority claimed from GB2019286.0A external-priority patent/GB2601752A/en
Application filed filed Critical
Publication of JP2023554198A publication Critical patent/JP2023554198A/ja
Publication of JP2023554198A5 publication Critical patent/JP2023554198A5/ja
Priority to JP2026061203A priority Critical patent/JP2026126216A/ja
Application granted granted Critical
Publication of JP7889870B2 publication Critical patent/JP7889870B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023559173A 2020-12-08 2021-12-07 発現ベクター組成物 Active JP7889870B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026061203A JP2026126216A (ja) 2020-12-08 2026-04-02 発現ベクター組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2019286.0A GB2601752A (en) 2020-12-08 2020-12-08 Expression vector
GB2019286.0 2020-12-08
PCT/GB2021/053191 WO2022123226A1 (en) 2020-12-08 2021-12-07 Expression vectors composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026061203A Division JP2026126216A (ja) 2020-12-08 2026-04-02 発現ベクター組成物

Publications (3)

Publication Number Publication Date
JP2023554198A JP2023554198A (ja) 2023-12-26
JP2023554198A5 true JP2023554198A5 (enExample) 2025-04-17
JP7889870B2 JP7889870B2 (ja) 2026-07-14

Family

ID=74175102

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023559173A Active JP7889870B2 (ja) 2020-12-08 2021-12-07 発現ベクター組成物
JP2026061203A Pending JP2026126216A (ja) 2020-12-08 2026-04-02 発現ベクター組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026061203A Pending JP2026126216A (ja) 2020-12-08 2026-04-02 発現ベクター組成物

Country Status (8)

Country Link
US (1) US20250277203A1 (enExample)
EP (1) EP4259215A1 (enExample)
JP (2) JP7889870B2 (enExample)
CN (1) CN116801912A (enExample)
AU (1) AU2021397865A1 (enExample)
CA (1) CA3200820A1 (enExample)
GB (1) GB2601752A (enExample)
WO (1) WO2022123226A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7588757B2 (en) * 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
CN100487124C (zh) * 2003-12-30 2009-05-13 首都医科大学 腺相关病毒介导三基因细胞表达体系
WO2006042090A1 (en) 2004-10-05 2006-04-20 Avigen, Inc. Stepped cannula
FI123451B (fi) 2008-11-17 2013-05-15 Sensinode Oy Menetelmä ja laite resurssien virtualisoimiseksi
AU2010316982B2 (en) * 2009-11-09 2013-09-12 Genepod Therapeutics Ab Novel viral vector construct for neuron specific continuous DOPA synthesis in vivo
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
EP3215191B1 (en) * 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
WO2017021359A1 (en) * 2015-08-03 2017-02-09 Myodopa Limited Systemic synthesis and regulation of l-dopa

Similar Documents

Publication Publication Date Title
US20220331409A1 (en) Factor ix gene therapy
JP7303287B2 (ja) 新規アデノ随伴ウイルスキャプシドタンパク質
Büeler Adeno-associated viral vectors for gene transfer and gene therapy
JP2025162557A5 (enExample)
IL278213B1 (en) A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
BR112020023292A2 (pt) vírus adeno-associado (aav), composição, método para a entrega de um transgene a uma célula, uso do aav, método para o tratamento de um indivíduo, vetor, célula, método para a produção de um vírus adeno-associado (aav), vírus adeno-associado (aav)
AU2018207259A1 (en) Polynucleotides and vectors for the expression of transgenes
JP2021528983A5 (enExample)
KR20240028976A (ko) 뇌에서 높은 발현 수준을 갖는 aav 조성물
US20250305001A1 (en) Genetic Construct
JP2022531861A5 (enExample)
WO2001036623A2 (en) Ecdysone-inducible adeno-associated virus expression vectors
Wang et al. Development of a novel recombinant adeno-associated virus production system using human bocavirus 1 helper genes
JP2023509443A5 (enExample)
JP2023553005A5 (enExample)
JP2025509971A (ja) 好ましい脳エンリッチメントを有する選択されたａａｖ組成物
JP2021534794A5 (enExample)
JP2023542241A5 (enExample)
WO2024220722A1 (en) Compositions and methods for tissue- specific expression of gene therapies
EP3390623A1 (en) Wilson's disease gene therapy
RU2019130004A (ru) Генная терапия при глазных заболеваниях
JP2020510433A5 (enExample)
JP2022525848A5 (enExample)
JP2022554141A5 (enExample)
JP2025509193A (ja) Ｇｌｐ－２受容体アゴニスト融合物をコードするウイルスベクター及び短腸症候群の治療におけるその使用